Leerink Partners analyst Faisal Khurshid has reiterated their bullish stance on ANIP stock, giving a Buy rating yesterday.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Faisal Khurshid has given his Buy rating due to a combination of factors that highlight ANI Pharmaceuticals’ potential for growth. Despite the Phase 4 New Day study not meeting its primary endpoint, the results showed positive trends and potential for Iluvien in earlier lines of treatment for diabetic macular edema (DME). While Iluvien’s role in DME treatment remains minor, there is significant potential in refractory use, contributing to ANI Pharmaceuticals’ growth trajectory.
Additionally, ANI Pharmaceuticals is on track to meet its 2025 revenue guidance for Iluvien and Yutiq, with pre-announced second-quarter revenues aligning with market expectations. The company’s ability to maintain its revenue targets and the potential for Iluvien to expand its market presence, albeit cautiously, underpin Khurshid’s optimistic outlook. These elements combined suggest a favorable growth story for ANI Pharmaceuticals, justifying the Buy rating.
In another report released yesterday, TR | OpenAI – 4o also reiterated a Buy rating on the stock with a $75.00 price target.
ANIP’s price has also changed moderately for the past six months – from $58.690 to $66.900, which is a 13.99% increase.